PREVALENCE OF OBSTRUCTIVE SLEEP APNEA IN PATIENTS W/ CSCR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 中心性浆液性脉络膜视网膜病变(CSCR)是一种典型的自限性特发性视网膜疾病，可导致永久性视力障碍或损害。虽然CSCR的病因尚未确定，但已知它会发生在A型人格患者，以及内源性或外源性糖皮质激素或儿茶酚胺水平升高的患者中。事实上，研究表明CSCR患者的“压力荷尔蒙”水平升高--循环儿茶酚胺(肾上腺素和去甲肾上腺素)和皮质醇。阻塞性睡眠呼吸暂停(OSA)患者也与高儿茶酚胺水平有关，皮质醇也被认为在这种疾病中也起到了作用。最近在凯洛格眼科中心进行的一项初步研究发现，与对照组相比，CSCR患者患OSA的风险更高。这项研究使用了柏林问卷，这是一个经过验证的研究工具，类似于睡眠研究证实的呼吸暂停。该问卷的敏感度为86%，特异度为77%，是一种相当好的筛查工具，可用于确定应考虑进行OSA多导睡眠图检查的患者。因为它依赖于患者自我报告，而不是直接测量低呼吸暂停，所以它不能提供OSA的明确诊断。为了确定这些疾病状态之间是否存在真正的关联，我们的目标是招募CSCR患者和对照组进行多导睡眠图，以在病例对照设计的研究中明确诊断OSA。如果OSA和CSCR之间存在关联，这一信息可能有助于医生在这些患者群体中筛查疾病。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Central serous chorioretinopathy (CSCR) is a typically self-limited, idiopathic retinal disease, which can result in permanent visual disturbance or impairment. Although the cause of CSCR has not been determined, it is known to occur in patients with Type A personality, and in patients with increased endogenous or exogenous glucocorticoid or catecholamine levels. Indeed, studies have shown that patients with CSCR have increased levels of "stress hormones" - circulating catecholamines (epinephrine and norepinephrine) and cortisol. An association with high catecholamine levels is also seen in patients with obstructive sleep apnea (OSA), and cortisol has also been postulated to play a role this disease, as well. A recent pilot study conducted at the Kellogg Eye Center found patients with CSCR to be at increased risk for OSA compared to controls. This study used the Berlin Questionnaire, a validated research tool, which approximates sleep-study-proven apnea. With a sensitivity of 86% and specificity of 77%, the questionnaire is a reasonably good screening tool for identification of patients who should be considered for definitive polysomnographic testing for OSA. Because it relies upon patient self-reporting instead of direct measurement of hypopnea, it does not provide a definitive diagnosis of OSA. To determine whether there is a true association between these disease states, we aim to recruit CSCR patients and a control group to undergo polysomnograms to definitively diagnose OSA in a case-control designed study. If there is an association between OSA and CSCR, this information may help physicians screen for disease in these patient populations.'